How to buy Covetrus stock - 17 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Covetrus stock

Own Covetrus stock in just a few minutes.

Covetrus, Inc is a health information services business based in the US. Covetrus shares (CVET) are listed on the NASDAQ and all prices are listed in US Dollars. Covetrus employs 5,275 staff and has a trailing 12-month revenue of around USD$4.3 billion.

How to buy shares in Covetrus

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Covetrus. Find the stock by name or ticker symbol: CVET. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Covetrus reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Covetrus, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Covetrus. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Covetrus share price

Use our graph to track the performance of CVET stocks over time.

Covetrus shares at a glance

Information last updated 2021-04-15.
52-week rangeUSD$7.51 - USD$40.775
50-day moving average USD$31.3317
200-day moving average USD$30.2494
Wall St. target priceUSD$34.2
PE ratio 40.8667
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.3

Buy Covetrus shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Covetrus stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Covetrus under- or over-valued?

Valuing Covetrus stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Covetrus's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Covetrus's P/E ratio

Covetrus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 41x. In other words, Covetrus shares trade at around 41x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Covetrus's PEG ratio

Covetrus's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.5172. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Covetrus's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Covetrus's EBITDA

Covetrus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$112 million.

The EBITDA is a measure of a Covetrus's overall financial performance and is widely used to measure a its profitability.

Covetrus financials

Revenue TTM USD$4.3 billion
Gross profit TTM USD$798 million
Return on assets TTM -0.99%
Return on equity TTM -1.2%
Profit margin -0.44%
Book value $11.3
Market capitalisation USD$4 billion

TTM: trailing 12 months

Shorting Covetrus shares

There are currently 5.5 million Covetrus shares held short by investors – that's known as Covetrus's "short interest". This figure is 5.6% down from 5.8 million last month.

There are a few different ways that this level of interest in shorting Covetrus shares can be evaluated.

Covetrus's "short interest ratio" (SIR)

Covetrus's "short interest ratio" (SIR) is the quantity of Covetrus shares currently shorted divided by the average quantity of Covetrus shares traded daily (recently around 909065.66666667). Covetrus's SIR currently stands at 6. In other words for every 100,000 Covetrus shares traded daily on the market, roughly 6000 shares are currently held short.

However Covetrus's short interest can also be evaluated against the total number of Covetrus shares, or, against the total number of tradable Covetrus shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Covetrus's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Covetrus shares in existence, roughly 40 shares are currently held short) or 0.0631% of the tradable shares (for every 100,000 tradable Covetrus shares, roughly 63 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Covetrus.

Find out more about how you can short Covetrus stock.

Covetrus share dividends

We're not expecting Covetrus to pay a dividend over the next 12 months.

Covetrus share price volatility

Over the last 12 months, Covetrus's shares have ranged in value from as little as $7.51 up to $40.775. A popular way to gauge a stock's volatility is its "beta".

CVET.US volatility(beta: 2.11)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Covetrus's is 2.1105. This would suggest that Covetrus's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Covetrus overview

Covetrus, Inc. , together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers. The company also offers value-added solutions that include, inventory management and e-commerce, as well as continuing education services for practitioners. In addition, it provides practice management software systems for veterinary practitioners and animal-health clinics, client communication services, reminders, data backup services, and hardware sales and support services. Further, the company engages in the distribution of finished goods pharmacy and specialty pharmaceutical compounding products, as well as shipping, manufacturer incentives, service fees, and data integration and support services. It serves animal-health and veterinary practices, and clinics in the companion-animal and equine markets primarily in North America, Europe, and the Asia Pacific.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site